The Aroon Indicator for DXCM entered a downward trend on September 22, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 101 similar instances where the Aroon Indicator formed such a pattern. In of the 101 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on September 14, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on DXCM as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DXCM turned negative on September 19, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for DXCM moved below the 200-day moving average on September 15, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.898) is normal, around the industry mean (24.932). P/E Ratio (100.000) is within average values for comparable stocks, (79.196). Projected Growth (PEG Ratio) (1.805) is also within normal values, averaging (6.230). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (11.468) is also within normal values, averaging (58.009).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of medical devices and glucose monitoring systems
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with SYK. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then SYK could also see price increases.
Ticker / NAME | Correlation To DXCM | 1D Price Change % | ||
---|---|---|---|---|
DXCM | 100% | +2.97% | ||
SYK - DXCM | 51% Loosely correlated | -4.81% | ||
PODD - DXCM | 48% Loosely correlated | +2.99% | ||
ABT - DXCM | 48% Loosely correlated | -1.27% | ||
ISRG - DXCM | 46% Loosely correlated | -0.86% | ||
RVTY - DXCM | 46% Loosely correlated | -1.76% | ||
More |
Ticker / NAME | Correlation To DXCM | 1D Price Change % |
---|---|---|
DXCM | 100% | +2.97% |
generic products (undefined stocks) | 50% Loosely correlated | +0.59% |
medical research (undefined stocks) | 50% Loosely correlated | +0.27% |
medical service (undefined stocks) | 49% Loosely correlated | +0.25% |
wearables (undefined stocks) | 47% Loosely correlated | +0.73% |
medical devices (undefined stocks) | 44% Loosely correlated | -0.61% |
More |